Lei X H, Tang Y Y, Li J, Mao Y M
Division of Gastroenterology and Hepatology, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai Institute of Digestive Disease, Shanghai 200001, China.
Zhonghua Gan Zang Bing Za Zhi. 2020 Feb 20;28(2):175-178. doi: 10.3760/cma.j.issn.1007-3418.2020.02.016.
Although tumor immune checkpoint inhibitors therapy brings survival benefits to cancer patients, it also faces many challenges, such as the occurrence of immune-mediated hepatotoxicity. Therefore, an in-depth understanding of the conditions, possible mechanisms, and risk factors that cause liver injury during the treatment of tumor immune checkpoint inhibitors will facilitate better clinical management.
尽管肿瘤免疫检查点抑制剂疗法给癌症患者带来了生存益处，但它也面临许多挑战，比如免疫介导的肝毒性的发生。因此，深入了解肿瘤免疫检查点抑制剂治疗期间导致肝损伤的情况、可能机制及危险因素，将有助于更好地进行临床管理。
